Compare Pfizer Inc (PFE) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Ulta Beauty Inc — how do they compare? Pfizer Inc trades at $27.72 (market cap $159.59B), while Ulta Beauty Inc trades at $562.39 (market cap $23.32B). The key difference: Pfizer Inc is far larger — about 6.8× Ulta Beauty Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Ulta Beauty Inc for 92 Days on average.
| PFE | ULTA | |
|---|---|---|
Market Cap | $159.59B | $23.32B |
Volume | 30,937,010 | 321,683 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $706.82 |
52-Week Low | $23.67 | $450.75 |
Typical Hold Time | 158 Days | 92 Days |
Enterprise Value | $211.09B | $25.63B |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
ULTA trades at $564.21, up 3.09% today, with a bullish technical outlook and strong analyst support. The stock has shown robust earnings beats in recent quarters, with Q1 and Q2 2026 exceeding expectations, and the company raised its 2026 guidance. Revenue growth is steady, though net margins have softened slightly from 12.17% in 2023 to 10.63% in 2025. Valuation ratios like a P/E of 19.86 and P/S of 1.86 appear reasonable relative to profitability metrics such as a 46.12% ROE.
The investment case hinges on execution of raised guidance and e-commerce momentum, but risks include margin pressure and flat store traffic. With a consensus price target of $624.93 implying ~11% upside and no sell ratings from analysts, the stock presents a growth opportunity tempered by near-term consumer and competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
